Phenols4Health Company Profile

Background

Phenols4Health is a research initiative focused on exploring the health benefits of extra virgin olive oil (EVOO), particularly its phenolic compounds. The project aims to assess how these compounds transfer into various foods during cooking and their potential to inhibit the formation of advanced glycation end-products (AGEs), which are linked to oxidative stress and inflammation-related diseases. Funded under the Marie Skłodowska-Curie Actions (MSCA) program, the project is coordinated by the University of Córdoba in Spain and involves collaboration with the Universidade Estadual de Campinas in Brazil.

Key Strategic Focus

The primary objective of Phenols4Health is to elucidate the health-promoting properties of EVOO by:

• Assessing Phenolic Transfer: Investigating how phenolic compounds from EVOO integrate into different foods during cooking processes.

• Inhibiting AGEs Formation: Evaluating the ability of these compounds to prevent the formation of AGEs, thereby reducing oxidative damage and inflammation.

• Utilizing Advanced Techniques: Employing advanced liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) to analyze the compounds and their effects.

• Economic Implications: Exploring potential economic benefits for the olive oil industry by enhancing the value of EVOO through its health benefits.

Financials and Funding

The Phenols4Health project is funded under the MSCA program, with a net EU contribution of €181,152.96. The project commenced on June 1, 2024, and is scheduled to conclude on May 31, 2026.

Pipeline Development

As a research initiative, Phenols4Health is not a commercial entity and does not have a product pipeline. However, the project is focused on:

• Food Applications: Developing methods to incorporate EVOO's phenolic compounds into various foods to enhance their health benefits.

• Health Impact Studies: Conducting studies to assess the impact of these enriched foods on human health, particularly concerning oxidative stress and inflammation.

Technological Platform and Innovation

Phenols4Health employs the following technological approaches:

• Advanced Analytical Techniques: Utilizing LC-MS/MS for precise identification and quantification of phenolic compounds and AGEs.

• Food Processing Innovations: Developing cooking methods that preserve and enhance the transfer of phenolic compounds from EVOO into foods.

• Health Assessment Models: Creating models to evaluate the effectiveness of phenolic-enriched foods in inhibiting AGE formation and reducing related health risks.

Leadership Team

The project is led by Dr. Ítala Marx, a postdoctoral researcher at the University of Córdoba. Dr. Marx holds a degree in Food Engineering from the Federal University of Technology – Paraná (UTFPR) in Brazil, a Master's in Food Quality and Safety from the Polytechnic Institute of Bragança (IPB) in Portugal, and a Ph.D. in Pharmaceutical Sciences, Nutrition, and Food Chemistry from the University of Porto (Portugal). She specializes in the health benefits of food components and has a strong background in food science and nutrition.

Competitor Profile

While Phenols4Health is a research project rather than a commercial company, it operates in a field with several key players:

• Indena: A private company specializing in plant-based active ingredients, with an estimated annual revenue of €100–200 million.

• IFF (International Flavors & Fragrances): A publicly traded company with a market capitalization of approximately $30–40 billion and annual revenue of $11–15 billion.

• Givaudan: A publicly traded company with a market capitalization of around CHF 25–35 billion and annual revenue of CHF 6–7 billion.

• Monteloeder: A private company with an estimated annual revenue of €15–40 million, focusing on nutraceuticals.

• Seprox Biotech: A private company with an estimated annual revenue of €2–12 million, specializing in niche hydroxytyrosol (HXT) supply.

• Bioiberica: A private company with historical annual revenues ranging from €130–200 million, offering bioactive ingredients.

• Seppic: A subsidiary of Air Liquide, with an estimated annual revenue of €400–800 million, focusing on cosmetic actives and extracts.

• Bioriginal: A private company with an estimated annual revenue of $30–80 million, distributing olive extracts and other ingredients.

These companies are involved in the production and distribution of phenolic compounds and related products, serving various industries such as food, cosmetics, and pharmaceuticals.

Strategic Collaborations and Partnerships

Phenols4Health is a collaborative project between the University of Córdoba in Spain and the Universidade Estadual de Campinas in Brazil. This partnership combines expertise in food science, nutrition, and analytical chemistry to advance the understanding of EVOO's health benefits.

Operational Insights

As a research initiative, Phenols4Health does not engage in commercial operations or compete directly in the market. Its focus is on scientific research and development, aiming to provide valuable insights into the health benefits of EVOO and its applications in food products.

Strategic Opportunities and Future Directions

Upon completion of the Phenols4Health project in May 2026, Dr. Ítala Marx is considering launching a start-up specializing in the production of functionally enriched foods. The goal is to develop new, nutritious, sustainable, and healthy products that create new revenue streams for olive oil producers. This venture would aim to offer consumers healthy, gluten-free snacks enriched with EVOO's phenolic compounds, leveraging the research findings from the project.